Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HTM | Q9NXG6 | 13/20 | 1.00 |
| ▸ | VHL | P40337 | 7/20 | 0.78 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3835307 | 0.99 | P4HTM (0.97) | P4HTMVHLEGLN1 | |
| SCHEMBL3597407 | 0.88 | VHL (1.00) | P4HTMVHLEGLN1 | |
| SCHEMBL3597325 | 0.83 | VHL (0.71) | P4HTMVHLEGLN1 | |
| SCHEMBL3601674 | 0.83 | VHL (0.73) | P4HTMVHLEGLN1 | |
| SCHEMBL3595365 | 0.82 | VHL (0.71) | P4HTMVHLEGLN1 | |
| SCHEMBL3591779 | 0.82 | VHL (0.71) | P4HTMVHLEGLN1 | |
| SCHEMBL8186022 | 0.82 | VHL (0.71) | P4HTMVHLEGLN1 | |
| SCHEMBL3592741 | 0.82 | VHL (0.71) | P4HTMVHLEGLN1 | |
| SCHEMBL3588274 | 0.81 | VHL (0.69) | P4HTMVHLEGLN1 | |
| SCHEMBL8257398 | 0.81 | VHL (1.00) | P4HTMVHLEGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2089380-B1 | SUBSTITUTED DIHYDROPYRAZOLONES AND USE THEREOF AS HIF-PROLYL-4 -HYDROXYLASE INHIBITORS | BAYER IP GMBH (DE) | 2016-06-29 | — | — | EP | disclosed |
| US-8524699-B2 | Substituted dihydropyrazolones and use thereof as HIF-prolyl-4-hydroxylase inhibitors | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-09-03 | — | — | US | disclosed |
| US-8524699-B2 | Substituted dihydropyrazolones and use thereof as HIF-prolyl-4-hydroxylase inhibitors | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-09-03 | — | — | US | disclosed |
| US-20120264704-A1 | SUBSTITUTED DIHYDROPYRAZOLONES AND USE THEREOF AS HIF-PROLYL-4 -HYDROXYLASE INHIBITORS | BAYER SCHERING PHARMA AG (DE) | 2012-10-18 | — | — | US | disclosed |
| US-20120264704-A1 | SUBSTITUTED DIHYDROPYRAZOLONES AND USE THEREOF AS HIF-PROLYL-4 -HYDROXYLASE INHIBITORS | BAYER SCHERING PHARMA AG (DE) | 2012-10-18 | — | — | US | disclosed |
| WO-2008049538-A1 | SUBSTITUTED DIHYDROPYRAZOLONES AND USE THEREOF AS HIF-PROLYL-4 -HYDROXYLASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264704-A1 | SUBSTITUTED DIHYDROPYRAZOLONES AND USE THEREOF AS HIF-PROLYL-4 -HYDROXYLASE INHIBITORS | HIF1AN, EGLN3, EGLN2 | P4HTM 8/4885VHL 7/4885EGLN1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.